Current Hematologic Malignancy Reports

• Myeloproliferative Neoplasms (B Stein, Section Editor)

Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?

Alain Antoine Mina, Brady Stein

• Myeloproliferative Neoplasms (B Stein, Section Editor)

Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms

Laura F. Mendez Luque, Amanda L. Blackmon, Gajalakshmi Ramanathan, Angela G. Fleischman

• Myeloproliferative Neoplasms (B Stein, Section Editor)

Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment

Hany Elmariah, Amy E. DeZern

• Myeloproliferative Neoplasms (B Stein, Section Editor)

Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions

Prathibha Surapaneni, Robyn M. Scherber

• Health Economics (N Khera, Section Editor)

Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?

Jennifer E. Vaughn, Veena Shankaran, Roland B. Walter

• Health Economics (N Khera, Section Editor)

Disparities in Survival and Health Outcomes in Childhood Leukemia

Lena E. Winestone, Richard Aplenc

• Multiple Myeloma (P Kapoor, Section Editor)

Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma

M. Offidani, M. Boccadoro, F. Di Raimondo, M. T. Petrucci, P. Tosi, M. Cavo

Targeting BTK in CLL: Beyond Ibrutinib

David A. Bond, Jennifer A. Woyach